Supplementary Figures 1 through 4 from Established T Cell–Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade
Year: 2023
Type: supplementary-materials
Abstract: Details additional immune correlative changes in treated MOC1 tumors, immune correlative changes in treated MOC2 tumors, and provides validation of the in vivo CTL assay.
Authors: Ellen Moore, Paul E. Clavijo, Ruth Davis, Harrison Cash, Carter Van Waes, Young Kim, Clint Allen
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362532864